Agathe Louisy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Agathe Louisy has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
Eiryann Humbert
Université François Rabelais, Tours, France
1 shared publication- Mahtab Samimi
Équipe Biologie des Infections à Polyomavirus, UMR INRAE ISP 1282 Université de Tours Tours France
1 shared publication
Latest Publications
- Top Cited Papers
- 15 September 2023
- Published by Springer Nature in American Journal of Clinical Dermatology
- Vol. 25 (1) , 35-53
Oral Lichen Planus: An Update on Diagnosis and Management
Oral lichen planus (OLP) is a chronic inflammatory disease whose pathogenesis involves a T-cell mediated, epithelium-directed inflammation in response to unknown antigen(s). The disease evolves by intermittent flares and displays polymorphous clinical features (reticular, erosive, atrophic, plaque, papular, bullous, etc.). When present, symptoms vary depending on the clinical form and range from discomfort to severe pain. Topical superpotent corticosteroids constitute the first-line treatment of symptomatic flares, whereas a wide range of second/third-line treatments are available among topical calcineurin inhibitors, systemic corticosteroids, systemic retinoids, topical/systemic immunomodulators, etc. Follow-up of patients is necessary to detect transformation into squamous cell carcinoma, occurring in approximately 1% of patients.
- 15 September 2023
- Published by Springer Nature in American Journal of Clinical Dermatology
- Vol. 25 (1) , 35-53
Top Cited PapersOral Lichen Planus: An Update on Diagnosis and Management
Oral lichen planus (OLP) is a chronic inflammatory disease whose pathogenesis involves a T-cell mediated, epithelium-directed inflammation in response to unknown antigen(s). The disease evolves by intermittent flares and displays polymorphous clinical features (reticular, erosive, atrophic, plaque, papular, bullous, etc.). When present, symptoms vary depending on the clinical form and range from discomfort to severe pain. Topical superpotent corticosteroids constitute the first-line treatment of symptomatic flares, whereas a wide range of second/third-line treatments are available among topical calcineurin inhibitors, systemic corticosteroids, systemic retinoids, topical/systemic immunomodulators, etc. Follow-up of patients is necessary to detect transformation into squamous cell carcinoma, occurring in approximately 1% of patients.